L5 Capital Inc. Amends BriaCell Therapeutics Stake Filing
Ticker: BCTXZ · Form: SC 13D/A · Filed: May 24, 2024 · CIK: 1610820
Sentiment: neutral
Topics: sec-filing, schedule-13d, amendment
Related Tickers: BCT
TL;DR
L5 Capital updated its BriaCell stake filing on 5/24. Keep an eye on BriaCell.
AI Summary
L5 Capital Inc. filed an amendment (No. 1) to its Schedule 13D on May 24, 2024, regarding its holdings in BriaCell Therapeutics Corp. The filing indicates a change in the date as of which the information is reported to May 24, 2024. Marc Lustig is identified as the person authorized to receive notices and communications for L5 Capital Inc.
Why It Matters
This amendment signals a potential shift in L5 Capital's investment strategy or reporting obligations concerning BriaCell Therapeutics, which could influence market perception and trading activity.
Risk Assessment
Risk Level: medium — Schedule 13D filings often indicate significant stake changes or activist intentions, which can introduce volatility and uncertainty for the subject company.
Key Numbers
- 1 — Amendment Number (Indicates this is the first amendment to the original filing.)
Key Players & Entities
- L5 Capital Inc. (company) — Filer of the Schedule 13D/A
- BriaCell Therapeutics Corp. (company) — Subject company of the filing
- Marc Lustig (person) — Person authorized to receive notices for L5 Capital Inc.
- May 24, 2024 (date) — Date of the filing amendment and date as of change
- May 14, 2024 (date) — Original date of the filing
FAQ
What specific changes were made in Amendment No. 1 to the Schedule 13D filing?
The filing indicates a change in the 'date as of change' to May 24, 2024, and is filed as Amendment No. 1.
Who is the subject company of this Schedule 13D/A filing?
The subject company is BriaCell Therapeutics Corp.
Who is the entity filing the Schedule 13D/A?
The entity filing is L5 Capital Inc.
What is the CUSIP number for BriaCell Therapeutics Corp. common shares?
The CUSIP number is 10778Y302.
Who is designated to receive notices and communications regarding this filing?
Marc Lustig, located at 1 First Canadian Place, Toronto, Ontario M5X 1H3 Canada, is authorized to receive notices and communications.
Filing Stats: 1,796 words · 7 min read · ~6 pages · Grade level 11.4 · Accepted 2024-05-24 08:58:04
Key Financial Figures
- $2.215 — le 13D) at a combined purchase price of $2.215 per common share and accompanying warra
- $2,000,000 — ant, for an aggregate purchase price of $2,000,000. The securities were purchased by L5 Ca
- $2.11 — ate of issuance at an exercise price of $2.11 and will expire on the five year annive
- $9,421,129.50 — 5 Capital Inc. expended an aggregate of $9,421,129.50 for the purchase of the common shares.
- $5.74 — mber 1, 2026, have an exercise price of $5.74 and vested immediately upon issuance.
- $6.03 — une 20, 2028, have an exercise price of $6.03 and vested immediately upon issuance.
- $5.21 — y L5 Capital Inc. The exercise price is $5.21 and expire on February 26, 2026. Item
Filing Documents
- formsc13da.htm (SC 13D/A) — 80KB
- 0001493152-24-021272.txt ( ) — 82KB
From the Filing
SC 13D/A 1 formsc13da.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* BriaCell Therapeutics Corp. (Name of Issuer) COMMON SHARES, NO PAR VALUE (Title of Class of Securities) 10778Y302 (CUSIP Number) Marc Lustig 1 First Canadian Place Toronto, Ontario M5X 1H3 Canada (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) May 14, 2024 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 10778Y302 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Marc Lustig 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS OO 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(e) or 2(f) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Canada NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 7 SOLE VOTING POWER 140,000 (1) 8 SHARED VOTING POWER 2,562,935 (2) 9 SOLE DISPOSITIVE POWER 140,000 (1) 10 SHARED DISPOSITIVE POWER 2,562,935 (2) 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,702,935 (1) (2) 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 14.7% (3) 14 TYPE OF REPORTING PERSON IN (1) Consists of 140,000 common shares upon the exercise of options held by Marc Lustig. (2) Consists of 2,542,935 common shares and 20,000 common shares upon exercise of warrants held by L5 Capital Inc. (3) Based on 18,284,661 shares outstanding as of May 21, 2024 and 140,000 common shares upon exercise of options and 20,000 common shares upon exercise of warrants. 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) L5 Capital Inc. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS WC 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(e) or 2(f) 6 CITIZENSHIP OR PLACE OF ORGANIZATION British Columbia, Canada NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 7 SOLE VOTING POWER 0 8 SHARED VOTING POWER 2,562,935 (1) 9 0 10 SHARED DISPOSITIVE POWER 2,562,935 (1) 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,562,935 (1) 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 14.% (2) 14 TYPE OF REPORTING PERSON CO (1) Consists of 2,542,935 common shares and 20,000 common shares upon exercise of warrants held by L5 Capital Inc. (2) Based on 18,284,661 shares outstanding as of May 21, 2024 and 20,000 common shares upon exercise of warrants. Item 1. Security and Issuer This Amendment No. 1 to Schedule 13D amends and supplements the Schedule 13D initially filed with the Securities and Exchange Commission on September 7, 2021 with respect to the common shares, no par value, of BriaCell Therapeutics Corp., a British Columbia corporation (the “Issuer”). The address of the principal executive office of the Issuer is Suite 300 – 235 15th Street, West Vancouver, BC V7T 2X1, Canada. All information contained in the Schedule 13D is, after reasonable inquiry and to the best of the Reporting Persons’ knowledge and belief, complete and correct as of the date hereof. Item 2. Identity and Background L5 Capital Inc. (a)-(c) L5 Capital Inc., which is sometimes referred to in this statement as a “Reporting Person,” is a corporation formed under the laws of the p